Torsemide

Torsemide

SCHEMBL4015063

Cc1cccc(Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C)c1.Cc1cccc(Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC12A1

The experimentally established mechanism targets of Torsemide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
TBXA2R P21731 10/20 1.00
KDM4E B2RXH2 1/20 1.00
CYP3A4 P08684 1/20 1.00
CYP2C9 P11712 1/20 1.00
HIF1A Q16665 1/20 1.00
PTGS1 P23219 2/20 0.53
PTGS2 P35354 2/20 0.53
ALDH1A1 P00352 1/20 0.52
BRS3 P32247 4/20 0.52
MAPT P10636 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Torsemide SCHEMBL29395363 1.00 TBXA2R (1.00) TBXA2RKDM4ECYP3A4CYP2C9HIF1A
Torsemide SCHEMBL41184 1.00 TBXA2R (1.00) TBXA2RKDM4ECYP3A4CYP2C9HIF1A
Torsemide SCHEMBL29369134 1.00 TBXA2R (1.00) TBXA2RKDM4ECYP3A4CYP2C9HIF1A
Torsemide SCHEMBL28460508 0.99 TBXA2R (0.98) TBXA2RKDM4ECYP3A4CYP2C9HIF1A
Torsemide SCHEMBL4838293 0.99 TBXA2R (0.98) TBXA2RKDM4ECYP3A4CYP2C9HIF1A
Torsemide SCHEMBL4827506 0.99 TBXA2R (0.98) TBXA2RKDM4ECYP3A4CYP2C9HIF1A
Torsemide SCHEMBL6315139 0.99 TBXA2R (0.98) TBXA2RKDM4ECYP3A4CYP2C9HIF1A
Torsemide SCHEMBL6307778 0.99 TBXA2R (0.98) TBXA2RKDM4ECYP3A4CYP2C9HIF1A
Torsemide SCHEMBL22687888 0.98 TBXA2R (0.96) TBXA2RKDM4ECYP3A4CYP2C9HIF1A
Torsemide SCHEMBL7256454 0.98 TBXA2R (0.96) TBXA2RKDM4ECYP3A4CYP2C9HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3137065-A2 COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES Pharnext (FR) 2017-03-08 EP disclosed
EP-3038614-A1 COMPOSITION COMPRISING TORASEMIDE AND BACLOFEN FOR TREATING NEUROLOGICAL DISORDERS Pharnext (FR) 2016-07-06 EP disclosed
WO-2015165948-A2 COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETIC NEUROPATHIES PHARNEXT (FR) 2015-11-05 WO disclosed
EP-2892519-A1 NOOTROPIC COMPOSITIONS FOR IMPROVING MEMORY PERFORMANCE Pharnext (FR) 2015-07-15 EP disclosed
EP-2892518-A2 NEW THERAPEUTIC APPROACHES FOR TREATING PARKINSON'S DISEASE Pharnext (FR) 2015-07-15 EP disclosed
WO-2015028659-A1 COMPOSITION COMPRISING TORASEMIDE AND BACLOFEN FOR TREATING NEUROLOGICAL DISORDERS PHARNEXT (FR) 2015-03-05 WO disclosed
EP-2819663-A1 NEW THERAPEUTIC APPROACHES FOR TREATING PARKINSON'S DISEASE Pharnext (FR) 2015-01-07 EP disclosed
WO-2014037412-A1 NOOTROPIC COMPOSITIONS FOR IMPROVING MEMORY PERFORMANCE PHARNEXT (FR) 2014-03-13 WO disclosed
WO-2014037416-A2 NEW THERAPEUTIC APPROACHES FOR TREATING PARKINSON'S DISEASE PHARNEXT (FR) 2014-03-13 WO disclosed
WO-2013127918-A1 NEW THERAPEUTIC APPROACHES FOR TREATING PARKINSON'S DISEASE PHARNEXT (FR) 2013-09-06 WO disclosed
EP-2560631-A2 BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROGICAL DISORDERS Pharnext (FR) 2013-02-27 EP disclosed
WO-2012117075-A2 TREATMENT OF CEREBRAL ISCHEMIA PHARNEXT (FR) 2012-09-07 WO disclosed
WO-2012117076-A2 BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROGICAL DISORDERS PHARNEXT (FR) 2012-09-07 WO disclosed
EP-1874286-A4 METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANXIETY DISORDERS NEUROTHERAPEUTICS PHARMA INC (US) 2009-07-01 EP disclosed
EP-1874286-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANXIETY DISORDERS Neurotherapeutics Pharma LLC (US) 2008-01-09 EP disclosed
WO-2006110187-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANXIETY DISORDERS NEUROTHERAPEUTICS PHARMA LLC (US) 2006-10-19 WO disclosed